FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to polyspecific antibody-like proteins, and can be used in medicine for therapy of cancer, autoimmune disease or infectious disease.
EFFECT: designed are recombinant penta-specific antibody-like proteins (miniGNC) containing a CD3-binding domain, which enables them to act as an activator that attracts T-cells, to change the direction of T-cell-mediated cytolysis and, finally, to destroy target cells.
10 cl, 6 dwg, 9 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| ANTI-CD19 ANTIBODIES AND METHODS FOR USE AND PRODUCTION THEREOF | 2021 |
|
RU2834996C1 |
| METHODS OF PRODUCING AND USING GUIDE AND NAVIGATION CONTROL PROTEINS | 2019 |
|
RU2824896C2 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| BISPECIFIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2787783C2 |
| LONG-ACTING FUSION PROTEIN GDF15 AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2836280C1 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
